VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells

Area of Science:

• Immunology
• Cancer Biology
• Biotechnology

Background:

• MHC class I polypeptide-related sequence A (MICA) activates NK cells but can be shed by cancer cells, leading to immune suppression.
• Cancer cells can evade NK cell-mediated immune surveillance by downregulating or shedding MICA.
• Targeting tumor-specific antigens is a strategy to overcome immune evasion.

Purpose of the Study:

• To design and evaluate a novel antibody-MICA fusion protein.
• To target tumor-specific vascular endothelial growth factor receptor 2 (VEGFR2) using a patented antibody (mAb04).
• To assess the fusion protein's efficacy in enhancing NK cell-mediated immunosurveillance.

Main Methods:

• Development of an antibody-MICA fusion protein based on anti-VEGFR2 mAb04.
• In vitro assessment of the fusion protein's antineoplastic and immunomodulatory activities.
• Evaluation of the fusion protein's effect on NK cell degranulation and cytokine production against K562 cells.

Main Results:

• The fusion antibody demonstrated retained antineoplastic and immunomodulatory activities.
• The fusion protein enhanced NK cell-mediated immunosurveillance against K562 cells.
• Increased NK cell degranulation and cytokine production were observed in the presence of the fusion protein.

Conclusions:

• The novel antibody-MICA fusion protein is a promising candidate for cancer-targeted immunotherapy.
• This approach may overcome MICA shedding-mediated immune suppression by cancer cells.
• Potential applications in chronic myeloid leukemia and other cancers warrant further investigation.